Bayer recently announced the top line results, and claimed that Rivaroxaban (Xarelto) plus standard therapy was observed to reduce the death rates, stroke as well as myocardial infarction, during a study of acute coronary syndrome. However, the company has claimed that the oral direct factor ‘Xa inhibitor’ has some properties that tend to increase risk of bleeding.

Renowned company, Johnson & Johnson, also works in collaboration with the company to market the Rivaroxaban, across the United States. In addition the FDA has approved the drug to avoid the incidents of deep vein thrombosis among patients receiving joint surgery.

Sources have confirmed that the FDA is evaluating its application to market the medication to obstruct the incidents of stroke, particularly among patients with non-valvular atrial fibrillation.

“As expectations for Xarelto in acute coronary syndrome were zero, this is a positive for Bayer”, explained a Bernstein Research.

While briefing about a latest blood-thinner, Xarelto, the Chief Executive Officer of Bayer, has notified that the drug was developed in collaboration with Johnson & Johnson.

Xarelto is believed to reduce the rates of heart attack, stroke as well as deaths due to cardiovascular diseases among patients living with acute coronary syndrome.